There are currently 1215 clinical trials in Pittsburgh, Pennsylvania looking for participants to engage in research studies. Trials are conducted at various facilities, including University of Pittsburgh, University of Pittsburgh Medical Center, Children's Hospital of Pittsburgh UPMC and Allegheny General Hospital. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
JAGUAR Trial: ObJective Analysis to GaUge EVAR Outcomes Through Randomization
NCT05064540
Recruiting
Prospective, randomized, multi-center study designed to evaluate the outcomes of commercially available contemporary EVAR in a real-world population. Patients will be randomized into two device cohorts and compared across the primary endpoints. Patients will be followed procedurally to discharge, at 1, 6, 12 months and annually through to 5 years (total follow-up commitment).
Gender:
All
Ages:
21 years and above
Trial Updated:
03/28/2024
Locations: Allegheny Health Network, Pittsburgh, Pennsylvania
Conditions: AAA, AAA - Abdominal Aortic Aneurysm
Register for Updates
Safety, Tolerability and Pharmacokinetics Study of KPG-818 in Hematological Malignancies Subjects
NCT04283097
Recruiting
This is a phase 1, multicenter, open-label, multiple-ascending dose study to evaluate the safety, pharmacokinetics and clinical activity of KPG-818 in subjects with hematological malignancies. Approximately 30 patients will be enrolled for dose escalation of 4 dose levels. Indication: Hematological malignancies (multiple myeloma [MM], mantle cell lymphoma [MCL], diffuse large B-cell lymphoma [DLBCL], adult T-cell leukemia-lymphoma [ATL], and indolent non Hodgkin lymphomas such as follicular lym... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
03/28/2024
Locations: UPMC CancerCenter, Pittsburgh, Pennsylvania
Conditions: Hematological Malignancies
Register for Updates
Tocilizumab Delivered Via Pleural and Peritoneal Catheters in Patients With Advanced Metastatic Cancer
NCT06016179
Recruiting
The purpose of this study to find out if tocilizumab can be safely infused into chest or abdominal cavities of patients with malignancy ascites (MA) or malignant pleural effusions (MPE). Patients will have a total of 4 doses, one dose administered each week. Each dose will be greater than the previous one.
Gender:
All
Ages:
Between 18 years and 89 years
Trial Updated:
03/27/2024
Locations: Allegheny Health Network Cancer Institute, Pittsburgh, Pennsylvania
Conditions: Malignant Pleural Effusion, Malignant Ascites
Register for Updates
Cold Agglutinin Disease Real World Evidence Registry
NCT05791708
Recruiting
This is a multinational, multi-center, observational, prospective, longitudinal disease registry designed to collect data on participants with cold agglutinin disease (CAD) or cold agglutinin syndrome (CAS). Among them, a minimum of 30 patients with CAD treated with sutimlimab are expected to take part in the sutimlimab cohort study. Patients with CAD who have been enrolled in previous sutimlimab clinical trials (e.g., BIVV009-01/LTS16214 [NCT02502903,CAD patients], BIVV009-03/EFC16215 [NCT03347... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
03/27/2024
Locations: University of Pittsburgh Medical Center-UPMC Hillman Cancer Center Site Number : 1210, Pittsburgh, Pennsylvania
Conditions: Cold Agglutinin Disease (CAD), Cold Agglutinin Syndrome (CAS)
Register for Updates
The Pregnancy 24/7 Cohort Study
NCT04749849
Recruiting
Moderate to vigorous intensity physical activity is known to reduce the risk of hypertensive disorders of pregnancy and other adverse pregnancy outcomes that increase future maternal cardiovascular disease risk (2018 Physical Activity Guidelines Advisory Committee, 2018; Davenport et al., 2018), yet less than 25% of pregnant women meet public health physical activity guidelines (Hesketh & Evenson, 2016). More than 95% of the 24-hour day is spent in sedentary behavior, sleep, or light-intensity a... Read More
Gender:
Female
Ages:
Between 18 years and 45 years
Trial Updated:
03/21/2024
Locations: University of Pittsburg, Pittsburgh, Pennsylvania
Conditions: Healthy
Register for Updates
Evaluating Length of Treatment With PD-1/PD-L1 Inhibitor in Advanced Solid Tumors
NCT04157985
Recruiting
Based on the overwhelming positive response to this survey and the large number of patients being treated with PD-1/PD-L1 therapy in the UPMC system, the investigators are proposing a trial that will randomize patients who have disease stability to stop treatment at 1 year or continue treatment until disease progression. The investigators anticipate that the results of this study will answer questions regarding the optimal duration of treatment. therapy.
Gender:
All
Ages:
18 years and above
Trial Updated:
03/19/2024
Locations: UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania
Conditions: Advanced Solid Tumors, NSCLC, Bladder Cancer, HNSCC, Renal Cancer, Melanoma, Anal Cancer, Colorectal Cancer, Cholangiocarcinoma, Gastric Cancer, Hepatocellular Carcinoma, Merkel Cell Carcinoma, Cervical Cancer
Register for Updates
A Study of TSR-022 in Participants With Advanced Solid Tumors (AMBER)
NCT06322693
Recruiting
This is a first-in-human study evaluating the anti-T cell immunoglobulin and mucin containing protein-3 (TIM-3) antibody TSR-022. The study will be conducted in 2 parts with Part 1 consisting of dose escalation and Part 2 dose expansion. Part 1 will determine the recommended Phase 2 dose (RP2D) of TSR-022 and Part 2 will evaluate the antitumor activity of TSR-022 in combination with TSR-042 or docetaxel and as monotherapy.
Gender:
All
Ages:
18 years and above
Trial Updated:
03/14/2024
Locations: GSK Investigational Site, Pittsburgh, Pennsylvania
Conditions: Neoplasms
Register for Updates
Pilot Brief Communal Coping Intervention for Adults With Type 1 Diabetes
NCT05925556
Recruiting
We plan to develop a communal coping intervention aimed at instilling a shared appraisal of diabetes and increasing patient-partner collaboration. To that end, we will pilot the first randomized clinical trial of a brief communal coping intervention among couples in which one person has T1D
Gender:
All
Ages:
18 years and above
Trial Updated:
03/14/2024
Locations: Carnegie Mellon University, Pittsburgh, Pennsylvania
Conditions: Diabetes Mellitus, Type 1
Register for Updates
Connective Tissue Matrix for Rotator Cuff Tendinopathy
NCT06160427
Recruiting
The purpose of this research study is to determine if the effectiveness of a single injection of CTM Boost in the treatment of patients with rotator cuff tendinopathy (RCT) is as effective as a single injection of platelet rich plasma (PRP) in reducing the symptoms of RCT.
Gender:
All
Ages:
Between 18 years and 80 years
Trial Updated:
03/14/2024
Locations: Allegheny Health Network Allegheny General Hospital, Pittsburgh, Pennsylvania +1 locations
Conditions: Tendinopathy, Shoulder Pain, Rotator Cuff Tendinitis, Rotator Cuff Tendinosis
Register for Updates
First in Human Study of Ziftomenib in Relapsed or Refractory Acute Myeloid Leukemia
NCT04067336
Recruiting
This first-in-human (FIH) dose-escalation and dose-validation/expansion study will assess ziftomenib, a menin-MLL(KMT2A) inhibitor, in patients with relapsed or refractory acute myeloid leukemia (AML) as part of Phase 1. In Phase 2, assessment of ziftomenib will continue in patients with NPM1-m AML.
Gender:
All
Ages:
18 years and above
Trial Updated:
03/13/2024
Locations: UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania
Conditions: Advanced Malignant Neoplasm, Acute Myeloid Leukemia, Mixed Lineage Leukemia, Mixed Lineage Acute Leukemia, Acute Leukemia of Ambiguous Lineage, Mixed Phenotype Acute Leukemia
Register for Updates
ALTERRA Post-Approval Study
NCT05378386
Recruiting
This study will monitor device performance and outcomes in subjects undergoing implantation of the Edwards SAPIEN 3 Transcatheter Pulmonary Valve System with Alterra Adaptive Prestent in the post-approval setting
Gender:
All
Ages:
All
Trial Updated:
03/12/2024
Locations: UPMC Children's Hospital of Pittsburgh, Pittsburgh, Pennsylvania
Conditions: Pulmonary Valve Insufficiency, Complex Congenital Heart Defect, Tetralogy of Fallot, Pulmonary Regurgitation, RVOT Anomaly
Register for Updates
Prototype DAA/TAA Vaccine Targeting MUC1 for Immune Interception and Prevention in Ductal Carcinoma In Situ
NCT06218303
Recruiting
Post-menopausal women with biopsy-proven DCIS will be enrolled into two cohorts. One cohort will receive neoadjuvant therapy with an aromatase inhibitor alone for about 12 weeks prior to surgery at 12 weeks. The second cohort will receive neoadjuvant therapy with an aromatase inhibitor and MUC1 vaccination (MUC1 peptide + Hiltonol®) pre-operatively at baseline, and weeks 2 and 10, followed by surgery at about 12 weeks. Patients in the vaccine cohort will be offered an optional boost vaccine 6 mo... Read More
Gender:
Female
Ages:
18 years and above
Trial Updated:
03/06/2024
Locations: UPMC Magee Womens Hospital, Pittsburgh, Pennsylvania
Conditions: Ductal Carcinoma in Situ
Register for Updates